conference Archives - Page 6 of 13

Progress of ctDNA in predicting prognosis of patients with urological tumors

By Peng Geng 2023.10.13

Circulating tumor DNA (ctDNA) for predicting tumor prognosis and guiding individualized treatment is a hot topic in malignant tumor research. ctDNA exists in the peripheral blood of tumor patients in a cell-free state and can dynamically evaluate the tumor condition, overcoming tumor heterogeneity biases. The 2023 American Association for Cancer Research (AACR) Annual Meeting was held from April 14 to 19, 2023, in Orlando, USA. In this AACR conference, three ctDNA-related studies evaluated its application value in urological tumors.

KEYNOTE-966 Study Published in “The Lancet”: Pembrolizumab Combined with Chemotherapy Brings Significant Survival Benefits to Advanced Biliary Tract Cancer Patients

By Peng Geng 2023.10.13

According to the KEYNOTE-966 study results announced at the 2023 American Association for Cancer Research (AACR) annual meeting, adding pembrolizumab on the basis of gemcitabine and cisplatin brings statistically and clinically significant survival benefits to patients with advanced biliary tract cancer. These results validate the outcomes of the randomized phase III TOPAZ-1 study. Encouragingly, this approach demonstrated consistent survival benefits across geographical regions and PD-L1 expression subgroups. The KEYNOTE-966 study results were concurrently published in "The Lancet."

Innovative Chinese Immunotherapy, Sintilimab Sets New Survival Records for Upper Gastrointestinal Cancers

By Peng Geng 2023.10.13

At the 2023 American Association for Cancer Research (AACR) annual meeting held on April 17, groundbreaking long-term follow-up data from studies on the Chinese innovative PD-1 inhibitor, Sintilimab, was unveiled. The findings span from phase III clinical trials for esophageal cancer (ORIENT-15) and gastric cancer (ORIENT-16). The results from these trials have set new longevity records for first-line treatments of these cancers in China.

IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence

By Peng Geng 2023.10.13

Recent findings from the phase III IMbrave050 trial presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting have unveiled a significant advancement in the treatment of hepatocellular carcinoma (HCC). The trial investigated the impact of adjuvant therapy with atezolizumab in combination with bevacizumab on recurrence-free survival (RFS) in HCC patients at high risk of recurrence following curative resection or ablation. The study's principal investigator, Professor Pierce Chow of the National Cancer Centre Singapore, revealed the trial's results, suggesting a potential paradigm shift in the management of high-risk HCC patients.

Prostate Cancer Radiation Therapy Research: SBRT vs Surgery; Conventional Radiation vs Large Fraction Radiation

By Peng Geng 2023.10.13

The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of prostate cancer radiation therapy, two phase 3 clinical studies were selected for oral presentation: The PACE-A study explores stereotactic body radiation therapy (SBRT) compared to surgery for localized prostate cancer; The CHHiP study further reports survival and comorbidity outcomes with a 12-year follow-up.

Key Insights from the 2023 ASCO-GU Conference on Sacituzumab Govitecan in Advanced Urothelial Cancer

By Peng Geng 2023.10.13

Advanced urothelial cancer (aUC) has seen remarkable progress in recent years with the emergence of antibody-drug conjugates (ADCs) targeting specific antigens. Trop-2, a cell surface antigen highly expressed in UC, has become a promising therapeutic target. Sacituzumab govitecan (SG), a next-generation Trop-2 ADC, received accelerated approval from the US FDA in April 2021 for treating adult patients with locally advanced or metastatic UC who had prior platinum-based chemotherapy and PD-(L)1 inhibitors. The 2023 ASCO-GU conference unveiled data from various cohorts of the TROPHY-U-01 trial and the latest advancements in UC treatment, encompassing late-line monotherapy, combination therapy, first-line combination therapy, and first-line maintenance therapy. Here, we summarize essential findings from these presentations, anticipating further insights after the conference.

Dr. Kan Gong: Research Progressin ASCO-GU 2023 Kidney Cancer

By Peng Geng 2023.10.13

The 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of kidney cancer diagnosis, a novel molecular imaging agent, 89Zr-DFO-girentuximab, has been shown to accurately diagnose clear cell renal cell carcinoma (ccRCC). In the first-line treatment area, the CheckMate 9ER study reported extended follow-up data, while the COSMIC-313 study presented data on IMDC subgroup patients. Additionally, research explored the improvement of complete response rates in first-line immunotherapy patients through local treatments and the benefits of reducing the number and duration of immunotherapy treatments for untreated survival. In the area of second-line treatment, CaboPoint reported positive anti-tumor activity of cabozantinib for immunotherapy-resistant patients.

Dr. Wei Yu: Research Progress in ASCO-GU 2023 Urothelial Carcinoma

By Peng Geng 2023.10.13

The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2023 (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. In the field of urothelial carcinoma (UC), significant progress has been made in research. Immunotherapy with immune checkpoint inhibitors (ICIs) in the first-line treatment for advanced UC, as reported in the final analysis of the IMvigor130 study, has provided more information on the population benefiting from immune therapy. Additionally, immunotherapy has expanded into early-stage treatment, with the updated 3-year follow-up data from the CheckMate 274 study showing a Disease-Free Survival (DFS) of up to 52.6 months in the PD-L1 > 1% subgroup. Furthermore, different targets such as Trop-2 and Nectin-4 in antibody-drug conjugates (ADCs) are being explored in various treatment modalities and are extending from later-line to first-line treatment.

Dr. Xinwei Wang: The Molecular Landscape and Clinical Significance of Liver Cancer

By Lynn 2023.10.13

Liver cancer is one of the most prevalent and deadliest cancers in China. Due to the low early diagnosis rate of liver cancer in clinical practice, treatment options such as radical liver resection and transplantation face significant limitations. In recent years, there has been a surge in liver cancer genomics research, providing new insights into early diagnosis, patient stratification, and treatment prognosis. From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Expert Conference (APPLE 2023) was held in Seoul, South Korea. During the conference, Dr. Xinwei Wang from the U.S. National Cancer Institute gave a special lecture on "The Molecular Landscape and Clinical Significance of Liver Cancer." Hepatology Digest had the privilege of inviting Dr. Wang to share recent significant developments in this research field and delve into the potential applications and prospects of liver cancer genomics research for early diagnosis and prognosis prediction.

Urinary Tumor DNA for MRD Detection in NMIBC rTURBT

By Peng Geng 2023.10.13

The American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU 2023) kicked off in San Francisco on February 16, 2023. On the second day of the conference, during a special session on urothelial carcinoma, Professor Kyle M. Rose from the H. Lee Moffitt Cancer Center presented a prospective study on using cfDNA/utDNA for MRD detection in NMIBC patients undergoing repeat-transurethral resection of bladder tumor (rTURBT).